Skip to main content
Donate

Research

Fast Funding

Treatment of Angelman Syndrome Using ASO targeting UBE3A-AS

$461,612 2017 M1801221: 2017-2018

Treatment of Angelman Syndrome Using ASO targeting UBE3A-AS

This program supported further exploration of various ASO candidates for paternal gene activation through antisense technology.

Principle Investigator

Scott Dindot, PhD

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.